Call Us Sign-Up/Sign-In
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

iCrowdNewswire Jan 26, 2021 7:00 AM ET

Depression Screening Market Size, Share By 2023 | Technology Development, Industry Growth, SWOT Analysis, Demands, Insights, Worldwide Service


iCrowd Newswire - Jan 26, 2021

Depression Screening Market Overview

Market Research Future (MRFR) states that the global depression screening market could expect to achieve a growth rate of 6.20% during the forecast period (2017-2023).

Depression Screening Market Drivers and Key Barriers

Depression is a type of a mental condition which leads to depressed mood, feelings of low self-worth, loss of interest, low energy, poor concentration, and disturbed sleep or appetite among individuals. A person suffering from depression experiences hopelessness, intense emotions of anxiety, helplessness, and negativity. MRFR estimates the worldwide depression screening market as a moderately expanding market, which could have better growth during the evaluation period.

Get customized Sample with complete Toc, Inclusive of COVID-19 Industry Analysis @ https://www.marketresearchfuture.com/sample_request/3806

Surging cases of patients with a number of mental disorders along with rise in stressful lifestyle positively impact the market. Other than this, hike in funding for research and development (R&D) as well as clinical trials favors the market. On this note, significant companies in the market are funding R&D to obtain effective solutions for mental health.

Esteemed vendors hold substantial portion of the market while owing to high investment cost, medium and small companies are predominantly stressing on the manufacturing of drugs instead of R&D. To illustrate, companies such as Pfizer Inc., Eli Lilly and Company and Allergan spend a rather huge amount on R&D, resulting in market growth.

Depression Screening Market Segmentation

The worldwide depression screening market can be segmented on the basis of disease type, diagnosis, treatment, and end user.

The types of diseases covered in the report include mood disorders, anxiety, bipolar disorders, depression, eating disorders, psychotic disorders, along with other mental and behavioral & disorders.

Diagnosis-based segments in the market are a psychological test, Lab tests, depression screening tests, and others.

Treatment-wise, the market includes brain-stimulation treatments (Vagus Nerve Stimulation (VNS), repetitive Transcranial Magnetic Stimulation (rTMS), Magnetic Seizure Therapy (MST), and Deep Brain Stimulation (DBS)), medication (anti-anxiety medications, antidepressants, antipsychotic medications, stimulants, anti-seizure medications and others), substance abuse treatment and others.

The end users in the market are medical research centers, hospitals and clinics, academic institutes, and others.

Depression Screening Market Regional Insight

The worldwide depression screening market comprises four main regions of Europe, the Americas, Middle East & Africa and Asia Pacific.

The Americas is the largest market for depression screening as the region houses some of the top pharmaceutical companies, leading to innovation and new solution development. Companies such as Pfizer Inc., Eli Lilly and Company, among others provide huge monetary support for R&D.  The Canadian Mental Health Association has released data that says that 1% of the Canadian population suffers from Schizophrenia, whereas close to 5% of the household population in the country deals with anxiety disorders.

Cases of mental disorder and illness are observing a sharp rise in Europe. The depression screening market in Europe has grown as a result of changing lifestyle and the rising prevalence of depression. Additionally, speedy rate of adoption of latest drugs and techniques could be another critical factor backing the market growth. The World Health Organization (WHO) says that nearly 27% of the adult population in the European Union (EU) countries suffers from severe form of depression.

In Asia Pacific, prevalence of several mental disorders is quickly increasing in middle-low income countries like India and China. The data published in International Journal of Behavioral Science reveals that depression, anxiety, substance abuse disorder, suicidal behavior and Post-Traumatic Stress Disorder (PTSD0 are the leading mental issues in Asia Pacific. With this surge in mental disorder cases, there has been a subsequent increase in the awareness levels regarding the treatment options. This is perceived to have a lucrative effect on the market growth in the following years.

Reluctance in adopting new therapies, restricted availability of healthcare facilities and low awareness of the disorders are some of the prime reasons for the slow market growth in Middle East and Africa.

Depression Screening Market Prominent Companies

The major players in the worldwide market are Novartis AG (Switzerland), Eli Lilly and Company (US), ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Otsuka Holdings Co. Ltd. (Japan), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (US), and others.

Depression Screening Industry Update

June 2019: The American Academy of Family Physicians recently unveiled a clinical practice guideline pertaining to the screening as well as treating of depression after acute coronary syndrome. It an updated replacement of the Academy’s guideline for detecting and treating depression after myocardial infarction.

Get Premium Research Report, Inclusive of COVID-19 Impact Analysis, Find more information @ https://www.marketresearchfuture.com/reports/depression-screening-mental-health-market-3806

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Contact Information:

Akash Anand
Market Research Future
+1 646 845 9312
sales@marketresearchfuture.com






Keywords:    COVID 19 Impact Analysis, Depression Screening Market 2021, Depression Screening Market Overview, Depression Screening Market Size, Depression Screening Market Report, Depression Screening Market Research, Depression Screening Market Growth, Depression Screening Market Analysis, Depression Screening Market Trends, Depression Screening Industry, Depression Screening Market Share, Depression Screening Market Demand, Depression Screening Market Opportunities, Depression Screening Market Outlook, Global Depression Screening Market

Tags:    Reportedtimes, iCN Internal Distribution, Research Newswire, English